• 130
  • 18
  • 收藏

Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds

Dow Jones2021-11-22

Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.

The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile "was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose."

BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论18

  • Jules_Huat
    ·2021-11-23
    Hmmm ok...
    回复
    举报
  • 小小仙女
    ·2021-11-23
    Like
    回复
    举报
  • 小小仙女
    ·2021-11-23
    Tell me your opinion about this news...
    回复
    举报
    收起
    • MengKeng
      it is good for little children who can be vaccinated and also people who hold Pfizer shares, haha
      2021-11-23
      回复
      举报
  • koolgal
    ·2021-11-23
    Pfizer & BioNTech will reap massive profits from vaccines alone since Covid-19 looks like it is here to stay.  Share prices of these 2 companies will also rise in tandem!  Go Pfizer! Go BioNTech! 🚀🚀🚀🌙🌙🌙
    回复
    举报
    收起
    • koolgal
      Thanks
      2021-11-23
      回复
      举报
    • 3f585b4d
      👍
      2021-11-23
      回复
      举报
    • koolgal
      Yes that is true
      2021-11-23
      回复
      举报
    查看更多 2 条评论
  • Dawang
    ·2021-11-22
    Time to protect our young tooo.;) Then travelling can truly take place.
    回复
    举报
    收起
    • Nez
      Yes
      2021-11-22
      回复
      举报
  • MHh
    ·2021-11-22
    As with the adult population, we don’t know the long term safety data. We know that in adults, efficacy lasts only about 6 months. Very disturbing data…
    回复
    举报
  • hpt
    ·2021-11-22
    Ok
    回复
    举报
  • Universe宇宙
    ·2021-11-22
    Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.
    回复
    举报
    收起
    • Universe宇宙回复RandyHall
      should aim higher, can it make people immune from covid virus, just like the smallpox vaccine that result in immunity from smallpox with 1 jab.
      2021-11-22
      回复
      举报
    • Universe宇宙
      is the study global or on certain countries?
      2021-11-22
      回复
      举报
    • Universe宇宙
      does it result in immunity against the covid virus?
      2021-11-22
      回复
      举报
    查看更多 2 条评论
  • Grit100
    ·2021-11-22
    Ok.
    回复
    举报
  • FALCON
    ·2021-11-22
    Like
    回复
    举报
  • Ermmmmmm
    ·2021-11-22
    Push for more revenue 
    回复
    举报
  • DZL
    ·2021-11-22
    yet another revenue wave boost for Pfizer, BioNTech 
    回复
    举报
    收起
    • Investcub
      Agreed, up up and away !
      2021-11-22
      回复
      举报
    • SmallYang
      agree
      2021-11-22
      回复
      举报
  • ThunderPat
    ·2021-11-22
    👍
    回复
    举报
  • HeroSmurf
    ·2021-11-22
    Moderna??
    回复
    举报
  • Kel9670ong
    ·2021-11-22
    Nice.. Finally the teenage can get some protection against covid
    回复
    举报
  • supergrowth
    ·2021-11-22
    Nice
    回复
    举报
    收起
  • BoonHuat
    ·2021-11-22
    Nice.
    回复
    举报
    收起
    • GlitterD
      Nice
      2021-11-22
      回复
      举报
  • WaitLongLong
    ·2021-11-22
    👍
    回复
    举报
    收起
 
 
 
 

热议股票

 
 
 
 
 

7x24